BioSpace News Archive

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”) , are pleased to announce that Dr. John Kellum, the Company’s CMO, will be featured as the keynote lecturer at the virtual 40th Vicenza Course.

Pressure BioSciences, Inc. reported that UST successfully created stable suspensions of milk-pea protein blends in microscopic particle sizes.

OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced they have entered an agreement to acquire Pega Medical, including its Fassier-Duval Telescopic Intramedullary System™ designed for patients suffering from Osteogenesis Imperfecta and other bone deformities.

Since the onset of the COVID-19 pandemic, diabetes care has been significantly impacted by the reduction in access to healthcare programs and services, resulting in a majority of people with diabetes experiencing mental health problems.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted US patent 11,337,987 for “Compositions and Methods for Treating Central Nervous System (CNS) Disorders” and US patent 11,370,811.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the online publication of a new study evaluating the efficacy and safety of ZYNRELEF.

AVM Biotechnology, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business Innovative Research (SBIR) grant.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Center.

Xenco Medical has expanded its ASC surgical device portfolio through the FDA clearance and launch of its Multilevel CerviKitTM,, an expansion of Xenco Medical’s breakthrough single-use cervical spine technology to include a comprehensive suite of implants and single-use instruments for 2, 3, and 4 level anterior cervical spine procedures.

Alpenglow Biosciences has announced the unveiling of their fully integrated offering with proprietary tissue preparation, advanced imaging technology and AI-powered, cloud-based 3D analysis.